Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the target of a significant decrease in short interest during the month of June. As of June 30th, there was short interest totaling 137,594 shares, a decrease of 72.1% from the June 15th total of 493,245 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average trading volume of 239,554 shares, the days-to-cover ratio is currently 0.6 days.

Indaptus Therapeutics Price Performance

Shares of INDP stock remained flat at $2.63 on Tuesday. 23,797 shares of the company traded hands, compared to its average volume of 511,426. The stock has a market cap of $297.82 million, a PE ratio of -0.17 and a beta of 1.11. The firm’s 50 day moving average is $2.53 and its two-hundred day moving average is $2.38. Indaptus Therapeutics has a 52 week low of $0.92 and a 52 week high of $12.77.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($1.87) by $1.64.

Institutional Investors Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 7.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on INDP shares. Wall Street Zen upgraded Indaptus Therapeutics to a “hold” rating in a report on Saturday, June 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.